Search clinical trials for: SPD489

Total 43 results

Shire

Completed

Safety, Tolerability, Pharmacokinetic, and Efficacy Study of SPD489 in Preschool Children With Attention-deficit/Hyperactivity Disorder

Attention Deficit Hyperactivity Disorder (ADHD)

United States
Shire

Completed

SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder

Major Depressive Disorder

United States, Chile, Australia, Argentina, United Kingdom
Shire

Terminated

Adjunctive SPD489 to Antipsychotic Medication in Clinically Stable Adults With Persistent Predominant Negative Symptoms of Schizophrenia

Schizophrenia

United States
Shire

Completed

Pharmacodynamic Profile of SPD489 in Healthy Adult Males Undergoing a Nocturnal Period of Acute Sleep Loss

Sleep Deprivation

United States
Shire

Completed

Safety and Efficacy Study in Preschool Children Aged 4-5 Years With Attention-deficit/Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder (ADHD)

United States
Shire

Withdrawn

A Study of SPD465 in Young Adult Drivers With Attention-Deficit Hyperactivity Disorder (ADHD) Using Driving Simulators

Attention Deficit Hyperactivity Disorder

United States
Shire

Completed

Efficacy, Safety, and Tolerability of SPD489 in Adults With Schizophrenia and Predominant Negative Symptoms

Schizophrenia and Predominant Negative Symptoms

United States
Shire

Withdrawn

SPD489 as Adjunctive Treatment in Adults With Negative Symptoms of Schizophrenia (NSS)

Negative Symptoms of Schizophrenia
Shire

Terminated

SPD489 Low Dose and High Dose Ranges When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia

Schizophrenia

United States
Shire

Completed

Prevention of Recurrence of Diverticulitis (PREVENT1)

Diverticulitis

New Zealand, United States, United Kingdom, Sweden, Australia, Israel, India, Spain, Colombia, Argentina, France
Shire

Completed

Prevention of Recurrence of Diverticulitis (PREVENT2)

Diverticulitis

United States, Italy, Germany, Canada, Brazil, Romania, Netherlands, Finland, South Africa, Hungary
Shire

Completed

Co-Administration of LDX (SPD489) and Venlafaxine XR (EFFEXOR XR) in Healthy Volunteers

Healthy

United States
Shire

Completed

Bioavailability Study of SPD489 Administered With Two Different Means of Administration in Healthy Adult Volunteers

Healthy Volunteers

United States
Shire

Completed

Safety and Efficacy of SPD489 on Executive Function Behaviors in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

ADHD Specifically With Executive Function Impairment

United States
Shire

Completed

Safety and Efficacy of Vyvanse in Adults With Attention-Deficit/Hyperactivity Disorder

Attention-Deficit/Hyperactivity Disorder

United States
Shire

Completed

Lisdexamfetamine Dimesylate 2-year Safety Study in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder (ADHD)

Germany, Italy, Poland, Spain, Romania, Belgium, Hungary, Netherlands, Sweden, United Kingdom
Shire

Completed

Forced-dose Titration of SPD489 in Adults With Binge Eating Disorder (BED)

Binge Eating Disorder

United States
Shire

Completed

Open Label Extension in Adults With Binge Eating Disorder (BED)

Binge Eating Disorder

Spain, United States, Germany
Shire

Completed

Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder

Binge Eating Disorder

United States, Spain, Germany, Canada, Sweden
Shire

Completed

Double-blind, Placebo-controlled, Randomised Withdrawal, Extension, Safety and Efficacy Study of LDX in Children and Adolescents Aged 6-17

ADHD

Germany, Hungary, Italy, Poland, Sweden, United States, United Kingdom, Belgium, France
Shire

Completed

SPD489 in Adults With Persistent Executive Function Impairments (EFI) and Partial or Full Remission of Recurrent Major Depressive Disorder

Major Depressive Disorder

United States
Shire

Completed

Assess the Safety and Pharmacokinetics of Ascending, Multiple Oral Doses of SPD489 in Adults With Schizophrenia

Schizophrenia

United States
Shire

Completed

Safety and Tolerability Study of SPD489 in Preschool Children Aged 4-5 Years, Diagnosed With Attention-deficit/Hyperactivity Disorder

Attention Deficit Hyperactivity Disorder (ADHD)

United States
Shire

Withdrawn

Safety and Efficacy of SPD489 in Adolescent Subjects Aged 13-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)

ADHD

United States
Shire

Completed

SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder

Binge Eating Disorder

United States, Germany
Shire

Completed

SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder

Binge Eating Disorder

United States, Spain, Germany, Sweden
Shire

Terminated

Long-term Safety of SPD489 When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia

Schizophrenia

United States
Shire

Completed

Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder

Major Depressive Disorder

United States, Spain, Canada, Puerto Rico, Croatia, Mexico
Shire

Completed

Effect of SPD422 on Platelet Lowering and Safety in Japanese Adults With At Risk Essential Thrombocythaemia

Essential Thrombocythemia (ET)

Japan
Shire

Terminated

SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension Study

Major Depressive Disorder

United States, Spain, Germany, Puerto Rico, Canada, Estonia, South Africa, Czechia, Finland, Chile, Hungary, Mexico, Poland, Romania
Shire

Completed

Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder

Attention-deficit/Hyperactivity Disorder

United States, Canada, Germany, Hungary, Sweden
Shire

Completed

Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder

Major Depressive Disorder

United States, Germany, Sweden, Poland, South Africa, Belgium, Czechia, Estonia, Finland, Hungary, Romania
Shire

Completed

Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder

Attention-deficit/Hyperactivity Disorder

United States
Shire

Completed

Long-term Safety of SPD422 in Japanese Adults With Essential Thrombocythaemia

Essential Thrombocythemia (ET)

Japan
Shire

Completed

Exploratory Study of SPD489 in Adults With Major Depressive Disorder (MDD) as Augmentation Therapy to an Antidepressant

Major Depressive Disorder

United States
Shire

Completed

A Study to Assess the Pharmacokinetics of Lanthanum Carbonate, Investigate and Compare the Efficacy, Safety and Tolerability of Lanthanum Carbonate With Calcium Carbonate in Hyperphosphataemic Children and Adolescents With Chronic Kidney Disease on Dialysis

Chronic Kidney Disease | Hyperphosphatemia

Germany, Argentina, Chile, Czechia, Hungary, Poland, Romania, Russian Federation, Turkey
Shire

Completed

Safety and Tolerability of SPD476 in Maintaining Remission in Patients With Ulcerative Colitis.

Colitis, Ulcerative
Shire

Completed

Safety and Pharmacokinetics of MMX Mesalamine in Children and Adolescents With Ulcerative Colitis

Ulcerative Colitis

United States, United Kingdom, Australia, Poland, Slovakia
Shire

Completed

Study to Evaluate the Effect of Omeprazole on the Pharmacokinetics of SPD422 (Anagrelide Hydrochloride) in Healthy Adult Participants

Healthy Volunteers

United States
Shire

Completed

Efficacy and Safety of SPD476 in Maintaining Remission in Patients With Ulcerative Colitis

Ulcerative Colitis

United States, Spain, Denmark, Korea, Republic of, Australia, Taiwan, Singapore, Sweden, Belgium, France, United Kingdom, Romania, New Zealand, India, Canada, South Africa, Brazil, Germany, Mexico, Hungary, Portugal, Chile, Netherlands and more
Shire

Completed

Phase II Dose-Ranging Study in Subjects With Mild to Moderate Ulcerative Colitis Treated With SPD476

Colitis, Ulcerative

Belgium
Shire

Completed

Efficacy and Safety of Two Doses of SPD476 (Mesalazine) 2.4g and 4.8g Once Daily, With Reference to Asacol 0.8g Three Times Daily in Subjects With Acute, Mild to Moderate Ulcerative Colitis

Ulcerative Colitis

Belgium
Shire

Completed

The Safety and Efficacy of SPD465 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)

Attention-Deficit/Hyperactivity Disorder

3

Subscribe